The extremely poor prognosis of patients is largely due to hepatocyte growth factor (HGF)/MET signaling, which promotes migration and invasion of glioblastoma (IDH wild-type; GBM; WHO grade 4).1,2 Clinical trials targeting MET, the only receptor of HGF, have yielded unimpressive results in GBM.3,4 Here we found that HGF induced strong chemotaxis on GBM cells, but MET expression was extremely low. We, therefore, used single-cell RNA sequencing (scRNA-seq) coupled with label-free proteome profiling to identify membrane proteins associated with HGF/MET signaling amplification in GBM and to provide a novel modulator, MPZL1, for HGF/MET-targeted therapy.